Compare TSHA & PSEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSHA | PSEC |
|---|---|---|
| Founded | 2019 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2020 | N/A |
| Metric | TSHA | PSEC |
|---|---|---|
| Price | $4.44 | $2.61 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 9 | 1 |
| Target Price | ★ $10.56 | $2.50 |
| AVG Volume (30 Days) | 2.3M | ★ 3.7M |
| Earning Date | 03-19-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 20.77% |
| EPS Growth | ★ 62.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,333,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.13 | $2.45 |
| 52 Week High | $6.02 | $4.28 |
| Indicator | TSHA | PSEC |
|---|---|---|
| Relative Strength Index (RSI) | 42.90 | 40.57 |
| Support Level | $4.39 | $2.55 |
| Resistance Level | $5.16 | $2.82 |
| Average True Range (ATR) | 0.19 | 0.08 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 32.53 | 31.03 |
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests mainly in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.